The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Abstract Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin‐like growth factor‐1. Anamorelin was not approved for use in Europe. In contrast, the use of anamorelin for cancer cachexia in f...
Saved in:
| Main Authors: | , , |
|---|---|
| 格式: | 圖書 |
| 出版: |
Wiley,
2021-02-01T00:00:00Z.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
| 索引號: |
A1234.567 |
|---|---|
| 復印件 1 | 可用 |